Emerging and Evolving Biomarkers: MRD




Speaker:

David Wu, MD, PhD

Moderator:

Lauren Ritterhouse, MD, PhD


This webinar is a recorded presentation of a live broadcast and includes the presentation, handout, and audience Q&A

Description:

This webinar will provide an introductory overview of measuring residual disease in myeloid neoplasms, with a focus on acute myeloid leukemia.  This talk will summarize the clinical need, laboratory approaches, and future opportunities and challenges for this testing.

Learning Objectives:

  • Review clinical need and opportunities for detecting measurable residual disease (MRD) in myeloid neoplasms, with focus on acute myeloid leukemia
  • Discuss challenges with detecting MRD
  • Describe technical approaches for detecting MRD in the clinical laboratory
  • Review recent literature and progress in this field

This webinar is part 6 of the Emerging and Evolving Biomarkers Series

This program has been supported through educational grant funding provided by Amgen and Loxo Oncology at Lilly (for further information concerning Lilly grant funding visit www.lillygrantoffice.com.) Supporting companies had no control over its content. No personally-identifiable information regarding you is provided to any grant supporters.


Recording Date: June 29, 2021
Duration: 1 Hour
Level of Instruction: Basic
CME/CMLE Credit: 1.0 
Last day to claim credit: December 31, 2022

How to claim credit: 

To earn CME/CMLE credit, all learners must watch the webinar and then complete the online survey.

AMA PRA Category 1 Credit(s)™

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Society for Clinical Pathology (ASCP) and Association for Molecular Pathology (AMP). The American Society for Clinical Pathology (ASCP) is accredited by the ACCME to provide continuing medical education for physicians.

The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours of CMLE credit. ASCP CMLE credit hours are acceptable for the ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity.


AMP is pleased to collaborate in the Immunotherapy Collaborative of Oncology Networked Communities, IC-ONC.  IC-ONC is a global information network in which multidisciplinary healthcare providers, responsible for treating patients with cancer, are connected via education.  

Please be sure to visit www.ic-onc.org to learn more about the collaborative and all it has to offer.


Note: Join the AMP Family for discounted access to the most current educational resources!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentation